Solidea Capital

Eric Baum, Co-Founder and Partner, appears to be the sole named investment decision-maker based on the firm's website. He concurrently serves as Managing Director of Acquis Consulting Group, the affiliated consultancy. The firm does not list any other investment professionals on its public team page.

Solidea sources deal flow primarily through its structural tie to Acquis Consulting Group. Because Acquis advises executive teams at both Fortune 50 companies and emerging ventures, Solidea can invest in companies where the consultancy has an existing operating relationship. Baum also participates in external angel and venture groups, such as the Charlotte Angel Fund, broadening the sourcing pipeline.

Solidea is structured as the private equity affiliate of a management consultancy, a hybrid that is neither a family office nor a traditional venture firm. It does not appear to raise blind-pool funds from external limited partners. Its investment capital is deployed alongside the strategic advisory work done by Acquis Consulting Group.

The firm's public profile points exclusively to direct deals and advisory board seats. The portfolio section on its website lists a single direct holding, Apiari. There is no mention of fund-of-fund commitments. Eric Baum's participation in the Charlotte Angel Fund suggests a secondary channel for accessing syndicated angel rounds, but this is framed as individual angel activity rather than a firm-level program.

Solidea tags its strategy as covering Early Stage, Seed, Start-up, and Growth. Its consulting-driven model means it can engage with companies pre-revenue through expansion. The firm's website does not break out check-size ranges by stage.

Eric Baum founded and leads a separate real estate investment firm that operates in several U.S. markets, distinct from Solidea Capital's venture and growth equity investments. The two activities share a common principal but appear to be run as independent pools of capital, with no public evidence of crossover investing between the strategies.

Solidea does not publicly describe a co-investment program. Its deal-by-deal model, linked to Acquis Consulting engagements, suggests capital is deployed on a proprietary basis. Board-level roles at Unrivaled Brands and Starton Therapeutics indicate the firm takes concentrated positions where it can apply its consulting expertise rather than passive sidecar stakes.